Search

Your search keyword '"Leary, Alexandra"' showing total 15 results
Start Over Author "Leary, Alexandra" Publisher bmj
15 results on '"Leary, Alexandra"'

1. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection

Author

Sanson, Claire, primary, Roosen, Alice, additional, Faron, Matthieu, additional, Zaccarini, François, additional, Maulard, Amandine, additional, Scherier, Stephanie, additional, Pautier, Patricia, additional, Leary, Alexandra, additional, Chargari, Cyrus, additional, Espenel, Sophie, additional, Genestie, Catherine, additional, Morice, Philippe, additional, and Gouy, Sebastien, additional

Published
2024
Full Text
View/download PDF

2. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

Author

Nebot-Bral, Laetitia, primary, Hollebecque, Antoine, additional, Yurchenko, Andrey A, additional, de Forceville, Louise, additional, Danjou, Mathieu, additional, Jouniaux, Jean-Mehdi, additional, Rosa, Reginaldo C A, additional, Pouvelle, Caroline, additional, Aoufouchi, Said, additional, Vuagnat, Perrine, additional, Smolenschi, Cristina, additional, Colomba, Emeline, additional, Leary, Alexandra, additional, Marabelle, Aurelien, additional, Scoazec, Jean-Yves, additional, Cassard, Lydie, additional, Nikolaev, Sergey, additional, Chaput, Nathalie, additional, and Kannouche, Patricia, additional

Published
2022
Full Text
View/download PDF

4. 355 Pembrolizumab and bevacizumab in platinum resistant epithelial ovarian cancer patients

Author

Michels, Judith, primary, Frenel, Jean-Sebastien, additional, Genestie, Catherine, additional, Ghiringhelli, François, additional, Brard, Caroline, additional, You, Benoit, additional, Floquet, Anne, additional, Eberst, Lauriane, additional, Bahleda, Rastilav, additional, Balleyguier, Corinne, additional, Paci, Angelo, additional, Ciccolini, Joseph, additional, Colomba, Emeline, additional, Pommeret, Fanny, additional, Massard, Christophe, additional, Pautier, Patricia, additional, Marabelle, Aurelien, additional, and Leary, Alexandra, additional

Published
2021
Full Text
View/download PDF

5. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)

Author

Banerjee, Susana, primary, Stewart, James, additional, Porta, Nuria, additional, Toms, Christy, additional, Leary, Alexandra, additional, Lheureux, Stephanie, additional, Khalique, Saira, additional, Tai, Jeremy, additional, Attygalle, Ayoma, additional, Vroobel, Katherine, additional, Lord, Christopher J, additional, Natrajan, Rachael, additional, and Bliss, Judith, additional

Published
2021
Full Text
View/download PDF

6. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

Author

Clamp, Andrew R, primary, Lorusso, Domenica, additional, Oza, Amit M, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Dean, Andrew, additional, Colombo, Nicoletta, additional, Weberpals, Johanne I, additional, Scambia, Giovanni, additional, Leary, Alexandra, additional, Holloway, Robert W, additional, Amenedo Gancedo, Margarita, additional, Fong, Peter C, additional, Goh, Jeffrey C, additional, O’Malley, David M, additional, Armstrong, Deborah K, additional, Banerjee, Susana, additional, García-Donas, Jesus, additional, Swisher, Elizabeth M, additional, Cameron, Terri, additional, Goble, Sandra, additional, Coleman, Robert L, additional, and Ledermann, Jonathan A, additional

Published
2021
Full Text
View/download PDF

7. Metabolic features of cancer cells impact immunosurveillance

Author

Joseph, Adrien, primary, Juncheng, Pan, additional, Mondini, Michele, additional, Labaied, Nizar, additional, Loi, Mauro, additional, Adam, Julien, additional, Lafarge, Antoine, additional, Astesana, Valentina, additional, Obrist, Florine, additional, Klein, Christophe, additional, Bloy, Norma, additional, Stoll, Gautier, additional, Signolle, Nicolas, additional, Genestie, Catherine, additional, Damotte, Diane, additional, Alifano, Marco, additional, Leary, Alexandra, additional, Pautier, Patricia, additional, Morice, Philippe, additional, Gouy, Sebastien, additional, Deutsch, Eric, additional, Chargari, Cyrus, additional, Dieu-Nosjean, Marie-Caroline, additional, Cremer, Isabelle, additional, Michels, Judith, additional, Kroemer, Guido, additional, and Castedo, Maria, additional

Published
2021
Full Text
View/download PDF

8. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

Author

Kristeleit, Rebecca S, primary, Oaknin, Ana, additional, Ray-Coquard, Isabelle, additional, Leary, Alexandra, additional, Balmaña, Judith, additional, Drew, Yvette, additional, Oza, Amit M, additional, Shapira-Frommer, Ronnie, additional, Domchek, Susan M, additional, Cameron, Terri, additional, Maloney, Lara, additional, Goble, Sandra, additional, Lorusso, Domenica, additional, Ledermann, Jonathan A, additional, and McNeish, Iain A, additional

Published
2019
Full Text
View/download PDF

10. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers

Author

Mueller, Jennifer J., primary, Lajer, Henrik, additional, Mosgaard, Berit Jul, additional, Bach Hamba, Slim, additional, Morice, Philippe, additional, Gouy, Sebastien, additional, Hussein, Yaser, additional, Soslow, Robert A., additional, Schlappe, Brooke A., additional, Zhou, Qin C., additional, Iasonos, Alexia, additional, Høgdall, Claus, additional, Leary, Alexandra, additional, O’Cearbhaill, Roisin E., additional, and Abu-Rustum, Nadeem R., additional

Published
2018
Full Text
View/download PDF

12. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Author

Belkhir, Rakiba, primary, Burel, Sébastien Le, additional, Dunogeant, Laetitia, additional, Marabelle, Aurélien, additional, Hollebecque, Antoine, additional, Besse, Benjamin, additional, Leary, Alexandra, additional, Voisin, Anne-Laure, additional, Pontoizeau, Clémence, additional, Coutte, Laetitia, additional, Pertuiset, Edouard, additional, Mouterde, Gaël, additional, Fain, Olivier, additional, Lambotte, Olivier, additional, and Mariette, Xavier, additional

Published
2017
Full Text
View/download PDF

14. Multimodal Treatment With Doxorubicin, Cisplatin, and Ifosfamide for the Treatment of Advanced or Metastatic Uterine Leiomyosarcoma: A Unicentric Experience

Author

Hadoux, Julien, primary, Rey, Annie, additional, Duvillard, Pierre, additional, Lhommé, Catherine, additional, Balleyguier, Corinne, additional, Haie-Meder, Christine, additional, Morice, Philippe, additional, Tazi, Youssef, additional, Leary, Alexandra, additional, Larue, Christine, additional, and Pautier, Patricia, additional

Published
2015
Full Text
View/download PDF

15. Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas.

Author

Kfoury M, Bonnet C, Delanoy N, Howarth K, Marzac C, Rouleau E, Micol JB, and Leary A

Abstract

There is a lack of biomarkers to predict outcome following initial treatment in patients with high-grade ovarian cancer. We hypothesized that monitoring TP53 mutation ( TP53m ) in circulating tumor DNA (ctDNA) could be a tumor-specific biomarker. Patients enrolled in a prospective study (NCT03010124) consented to analysis of biological samples through the disease course. ctDNA was extracted and analyzed to detect the presence of TP53m Next-generation sequencing was performed on tumor tissue to detect TP53m and on whole blood to detect clonal hematopoiesis of indeterminate potential (CHIP).A total of 102 samples were sequentially collected from 26 patients. ctDNA was detected in all patients at diagnosis. The same TP53m was found in ctDNA and tumor tissue in 77% of patients. TP53m in ctDNA was not CHIP related. During neoadjuvant chemotherapy, increasing ctDNA was associated with failure to achieve complete interval cytoreductive surgery in 60% of patients. Rising ctDNA or de novo TP53m seemed to be associated with a trend for worst survival compared with decrease or complete clearance: progression-free survival 10 versus 26.5 months, HR 3.2. Despite macroscopically complete surgery, 30% of patients had detectable ctDNA post-operatively and had worse survival than those with undetectable ctDNA. Monitoring TP53m in ctDNA during chemotherapy or after surgery could help guide the best adjuvant therapy., Competing Interests: Competing interests: MK: advisory boards/honoraria: GSK, AstraZeneca; travel, accommodations: Pfizer, GSK, Eisai. ND: travel, accommodations: GSK; advisory boards/honoraria: GSK, AstraZeneca, MSD, Clovis Oncology, EISAI. KH: shareholder/stockholder/stock options, full/part-time employment: Inivata. ER: honoraria: AstraZeneca (Inst), Roche (Inst), BMS (Inst), GlaxoSmithKline (Inst), Clovis Oncology (Inst); consulting or advisory role: AstraZeneca; research funding: AstraZeneca (Inst); travel, accommodations, expenses: AstraZeneca, BMS. JBM : honoraria: Jazz Pharmaceuticals, Astellas Pharma; consulting or advisory role: AbbVie, Servier; travel, accommodations, expenses: AbbVie. AL: honoraria (self): Medscape; AZ, Clovis, GSK, Kephren; advisory/consultancy: AZ, Clovis, GSK, Biocad, Ability Pharma, Merck Serono, Tesaro, MSD, Seattle Genetics, Gamamabs, Gritstone; research grant/funding (self): Inivata, Sanofi, AZ, OSE Immuno; travel/accommodation/expenses: AZ, Roche, Clovis, Tesaro. All other authors have declared no conflicts of interest., (© IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results